Details of the Drug

General Information of Drug (ID: DMVRIC2)

Drug Name
Zileuton
Synonyms
Leutrol; Zileutonum; Ziluton; Zyflo; Abbott brand of zileuton; Zyflo CR; Zyflo Filmtab; A 64077; Abbot 64077; Abbott 64077; A-64077; ABBOTT-64077; ABT-077; CTI-02; ZYFLO (TN); ZYFLO, Zileuton; Zileutonum [INN-Latin]; Zyflo (TN); Zileuton (USP/INN); Zileuton [USAN:INN:BAN]; N-[1-(benzo[b]thiophen-2-yl)ethyl]-N-hydroxyurea; N-(1-Benzo(b)thien-2-ylethyl)-N-hydroxyurea; (+-)-1-(1-Benzo(b)thien-2-ylethyl)-1-hydroxyurea; (+-)-1-(1-Benzo[b]thien-2-ylethyl)-1-hydroxyurea; (+/-)-1-(1-Benzo[b]thien-2-ylethyl)-1-hydroxyurea; 1-[1-(1-benzothien-2-yl)ethyl]-1-hydroxyurea; 1-[1-(1-benzothiophen-2-yl)ethyl]-1-hydroxyurea
Indication
Disease Entry ICD 11 Status REF
Allergic asthma CA23.0 Approved [1]
Asthma CA23 Approved [2]
Intrinsic asthma N.A. Approved [1]
Therapeutic Class
Antiinflammatory Agents
Affected Organisms
Humans and other mammals
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 236.29
Logarithm of the Partition Coefficient (xlogp) 1.6
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
Absorption
The drug is rapidly and almost completely absorbed []
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Clearance
The apparent oral clearance of drug is 7 mL/min/kg []
Half-life
The concentration or amount of drug in body reduced by one-half in 2.5 hours [4]
Metabolism
The drug is metabolized via the hepatic []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 169.28029 micromolar/kg/day [5]
Vd
The volume of distribution (Vd) of drug is 1.2 L/kg []
Water Solubility
The ability of drug to dissolve in water is measured as 0.5 mg/mL [3]
Chemical Identifiers
Formula
C11H12N2O2S
IUPAC Name
1-[1-(1-benzothiophen-2-yl)ethyl]-1-hydroxyurea
Canonical SMILES
CC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O
InChI
InChI=1S/C11H12N2O2S/c1-7(13(15)11(12)14)10-6-8-4-2-3-5-9(8)16-10/h2-7,15H,1H3,(H2,12,14)
InChIKey
MWLSOWXNZPKENC-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
60490
ChEBI ID
CHEBI:10112
CAS Number
111406-87-2
UNII
V1L22WVE2S
DrugBank ID
DB00744
TTD ID
D09JUG
INTEDE ID
DR1730
ACDINA ID
D00740
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Arachidonate 5-lipoxygenase (5-LOX) TT2J34L LOX5_HUMAN Inhibitor [6]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [7]
Cytochrome P450 2C9 (CYP2C9)
Main DME 		DE5IED8 CP2C9_HUMAN Substrate [8]
Cytochrome P450 1A2 (CYP1A2)
Main DME 		DEJGDUW CP1A2_HUMAN Substrate [9]
Prostaglandin G/H synthase 1 (COX-1) DE073H6 PGH1_HUMAN Substrate [7]
UDP-glucuronosyltransferase 1A9 (UGT1A9) DE85D2P UD19_HUMAN Substrate [7]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
11-beta-hydroxysteroid dehydrogenase type 2 (HSD11B2) OTHF4H9U DHI2_HUMAN Gene/Protein Processing [10]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Gene/Protein Processing [11]
Caspase-7 (CASP7) OTAPJ040 CASP7_HUMAN Gene/Protein Processing [11]
Cytochrome P450 1A2 (CYP1A2) OTLLBX48 CP1A2_HUMAN Gene/Protein Processing [12]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Gene/Protein Processing [13]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Protein Interaction/Cellular Processes [14]
Multidrug resistance-associated protein 1 (ABCC1) OTGUN89S MRP1_HUMAN Drug Response [15]
Polyunsaturated fatty acid 5-lipoxygenase (ALOX5) OT7FOIK2 LOX5_HUMAN Gene/Protein Processing [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Allergic asthma
ICD Disease Classification CA23.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Arachidonate 5-lipoxygenase (5-LOX) DTT ALOX5 1.00E-02 0.55 2.11
Cytochrome P450 1A2 (CYP1A2) DME CYP1A2 7.68E-02 -2.10E-01 -6.42E-01
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 4.28E-02 -1.99E-01 -6.09E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 9.81E-01 2.72E-01 6.95E-01
Prostaglandin G/H synthase 1 (COX-1) DME PTGS1 7.25E-01 -4.31E-02 -5.74E-02
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Breast Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MCF-7 CTRP1 9.0685 10.9022 8.1452 8.193
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SF295 CTRP1 6.6949 8.602 4.3937 1.7522
GaMG CTRP1 7.5285 9.2275 4.5072 0.444
LN-229 CTRP1 10.5889 16.7519 6.4009 16.4479
Cancer Drug Sensitivity Data Curated from 10 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HEC-265 CTRP1 5.9482 9.648 3.4566 10.9288
HEC-6 CTRP1 6.0269 8.6073 4.0121 6.0811
HEC-108 CTRP1 7.0304 8.6021 4.5407 0.6293
HEC-59 CTRP1 7.0743 8.562 4.5725 0.4809
KLE CTRP1 7.1107 9.2936 4.3092 1.6926
HEC-251 CTRP1 7.2574 12.5822 2.9335 10.9694
MFE-319 CTRP1 7.5045 12.9429 2.9207 10.42
HEC-151 CTRP1 8.2115 12.146 6.7626 23.6833
JHUEM-2 CTRP1 9.1801 10.6079 8.383 5.6086
Ishikawa (Heraklio) 02 ER- CTRP1 5.7037 8.2644 3.9565 7.5396
⏷ Show the Full List of 10 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 24 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MC116 CTRP1 5.8108 6.7833 4.7134 1.0619
KE-97 CTRP1 6.0659 8.2941 4.1836 4.5599
BL-70 CTRP1 6.0709 9.9657 3.3891 11.0671
HT CTRP1 6.3049 9.8999 3.5815 8.8051
P3HR-1 CTRP1 6.3788 10.8881 3.1575 11.879
Ku812 CTRP1 7.9096 9.5034 4.549 0.2015
PL21 CTRP1 7.9905 10.2516 7.4395 19.6735
KMS-11 CTRP1 8.3536 12.0851 6.9241 21.7852
GDM-1 CTRP1 8.3715 10.7385 7.5947 16.3043
LP-1 CTRP1 8.4051 13.0498 6.4954 24.4978
NU-DUL-1 CTRP1 8.6596 9.891 8.2765 8.8996
OCI-AML-3 CTRP1 8.8425 10.0763 8.3602 7.2545
EJM CTRP1 8.8931 11.689 7.6032 13.7388
SU-DHL-5 CTRP1 8.9248 9.591 8.6742 4.065
U-937 CTRP1 8.9447 15.2138 5.8858 25.5819
NOMO-1 CTRP1 8.9457 9.8742 8.5535 5.0466
RPMI-8226 CTRP1 8.9655 10.7721 8.1233 8.8249
MOLM-16 CTRP1 8.975 10.4047 8.3149 7.0611
SKM-1 CTRP1 8.9917 10.0869 8.4879 5.4312
AMO1 CTRP1 9.0639 9.9154 8.6349 3.8009
THP-1 CTRP1 9.0898 10.2407 8.4935 4.969
OCI-Ly10 CTRP1 9.3026 13.0985 7.2384 15.057
WSU-DLCL2 CTRP1 9.4966 11.7904 8.0385 7.5242
SU-DHL-4 CTRP1 9.557 14.5505 6.7164 17.9636
⏷ Show the Full List of 24 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Kidney Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
VMRC-RCW CTRP1 6.8492 9.6904 4.01 4.1079
RCC10RGB CTRP1 9.4336 10.6185 8.565 3.1189
Cancer Drug Sensitivity Data Curated from 37 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
DLD-1 CTRP1 5.8766 7.265 4.5397 2.187
LS513 CTRP1 5.9511 7.7555 4.3616 3.4102
SW48 CTRP1 6.2627 10.1742 3.4216 10.2031
COLO205 CTRP1 6.8868 8.0308 4.6903 0.2189
LS411N CTRP1 6.893 8.0667 4.6801 0.2423
SK-CO-1 CTRP1 7.1458 8.7749 4.5231 0.6163
GP2d CTRP1 7.227 8.6266 4.6069 0.2976
SNU-C2A CTRP1 7.3625 10.6876 3.8532 4.2211
C2BBe1 CTRP1 7.505 9.9977 4.2087 1.7714
SNU-C4 CTRP1 7.7557 10.2776 7.1861 23.0713
SNU-C5 CTRP1 7.9794 10.9987 7.089 22.5319
SW620 CTRP1 8.2495 12.46 6.6442 24.3017
CW-2 CTRP1 8.4905 10.1599 7.9845 12.3228
COLO 320 CTRP1 8.5492 15.1835 5.5622 28.9374
SNU-175 CTRP1 8.7046 9.5752 8.4677 7.0024
LS180 CTRP1 8.7193 10.4122 8.0819 10.3182
SNU-81 CTRP1 8.9644 10.7097 8.1535 8.5586
HCT 116 CTRP1 9.0302 10.6457 8.2415 7.4863
MDST8 CTRP1 9.1122 11.2405 8.0122 9.2065
LoVo CTRP1 9.1199 12.4091 7.4343 14.2018
HT-55 CTRP1 9.1722 10.3438 8.5082 4.5136
SNU-1040 CTRP1 9.1861 11.0559 8.1643 7.5493
KM12 CTRP1 9.1918 10.5684 8.4119 5.3043
RKO CTRP1 9.1982 10.6734 8.3646 5.7046
HT115 CTRP1 9.2201 10.4944 8.4706 4.6716
HCT 8 CTRP1 9.2511 10.7721 8.3567 5.5761
SW948 CTRP1 9.2559 11.2818 8.107 7.7929
CL-34 CTRP1 9.2772 10.4716 8.5252 3.979
SNU-61 CTRP1 9.29 11.9635 7.7944 10.4308
NCI-H508 CTRP1 9.3747 10.643 8.5121 3.7648
RCM-1 [Human ESC] CTRP1 9.4022 10.6674 8.5197 3.6094
SW480 CTRP1 9.7324 14.7071 6.7745 16.8922
LS123 CTRP1 9.8091 11.6137 8.3395 3.9563
COLO 678 CTRP1 9.8669 14.6308 6.9143 15.3986
HT-29 CTRP1 9.9216 12.8288 7.8354 7.8772
SW403 CTRP1 9.9542 16.5571 2.6948 6.8759
CL-40 CTRP1 10.6017 12.2042 8.5107 1.186
⏷ Show the Full List of 37 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 4 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JHH-6 CTRP1 6.5174 7.2828 4.8148 0.075
SNU-449 CTRP1 7.622 9.24 4.5372 0.319
SNU-398 CTRP1 8.684 9.5356 8.4648 7.1398
Hep-G2 CTRP1 9.3217 10.5965 8.4966 4.0787
Cancer Drug Sensitivity Data Curated from 91 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
LC-1/sq-SF CTRP1 5.8763 8.3942 4.0134 6.5102
NCI-H1930 CTRP1 5.9497 9.4783 3.5404 10.2414
BEN CTRP1 6.1265 7.504 4.5697 1.4985
NCI-H2126 CTRP1 6.3307 9.5859 3.7472 7.3988
COR-L51 CTRP1 6.3422 30.6864 -4.0947 48.2478
NCI-H522 CTRP1 6.3873 10.3611 3.4164 9.867
NCI-H2029 CTRP1 6.4521 8.4086 4.3531 2.4147
NCI-H810 CTRP1 6.471 9.5227 3.8653 6.0799
Calu-6 CTRP1 6.519 8.8299 4.2062 3.3416
COR-L279 CTRP1 6.5249 8.3394 4.4193 1.8461
HCC33 CTRP1 6.6205 8.7767 4.2835 2.5963
LCLC-103H CTRP1 6.6208 8.7004 4.3161 2.3729
NCI-H1915 CTRP1 6.6739 11.4963 3.0663 11.6592
HCC78 CTRP1 6.7087 9.0961 4.1928 3.0692
NCI-H1975 CTRP1 6.7123 10.3352 3.6383 7.2375
DV-90 CTRP1 6.7597 8.7717 4.3554 1.896
SHP-77 CTRP1 6.7866 12.9158 2.4605 15.4542
NCI-H358 CTRP1 6.7963 9.5579 4.0391 4.0037
Lu-65 CTRP1 6.8295 8.9342 4.3223 1.9998
HCC44 CTRP1 6.8481 8.8172 4.3788 1.6294
NCI-H1048 CTRP1 6.8528 11.3169 3.2687 9.6651
NCI-H1568 CTRP1 6.9136 9.7283 4.0286 3.8451
ChaGo-K-1 CTRP1 6.9749 10.0586 3.9174 4.524
VMRC-LCD CTRP1 6.9781 8.6797 4.4903 0.8911
NCI-H1373 CTRP1 7.0103 10.2817 3.8386 5.0253
HARA [Human squamous cell lung carcinoma] CTRP1 7.0353 9.2606 4.2874 1.9195
NCI-H23 CTRP1 7.0468 9.5115 4.1898 2.5101
NCI-H1573 CTRP1 7.0918 8.8261 4.4823 0.827
NCI-H1437 CTRP1 7.1206 10.4921 3.8071 5.0219
EBC-1 CTRP1 7.1238 9.241 4.3361 1.5256
NCI-H2405 CTRP1 7.1469 10.157 3.9677 3.8304
NCI-H1355 CTRP1 7.161 12.0787 3.1079 10.0067
NCI-H1793 CTRP1 7.1785 9.131 4.4029 1.1174
EPLC-272H CTRP1 7.1818 10.0042 4.051 3.2006
NCI-H82 CTRP1 7.1998 12.3016 3.0283 10.465
NCI-H2009 CTRP1 7.216 9.7095 4.1905 2.253
DMS 273 CTRP1 7.2206 8.5971 4.6148 0.2795
NCI-H727 CTRP1 7.2342 9.1529 4.4182 0.9922
Calu-3 CTRP1 7.2392 9.6502 4.2255 2.0103
NCI-H2286 CTRP1 7.2409 8.6273 4.6116 0.2795
NCI-H1944 CTRP1 7.2455 10.0557 4.0616 3.0244
COR-L88 CTRP1 7.2597 8.8725 4.532 0.5102
NCI-H650 CTRP1 7.2711 9.3383 4.363 1.2218
Lu-99 CTRP1 7.3035 8.7885 4.5783 0.3424
KNS-62 CTRP1 7.3077 11.5795 3.4273 7.3577
NCI-H1435 CTRP1 7.314 9.5304 4.3071 1.4624
COLO 668 CTRP1 7.3885 9.0809 4.5065 0.5218
RERF-LC-KJ CTRP1 7.4448 9.2549 4.4654 0.6325
LXF 289 CTRP1 7.5391 9.3515 4.467 0.5685
NCI-H1299 CTRP1 7.5545 10.6582 3.964 3.1589
NCI-H661 CTRP1 7.5642 9.5532 4.4034 0.7873
A-549 CTRP1 7.5865 10.8175 3.9134 3.4317
LCLC-97TM1 CTRP1 7.6216 9.5259 4.4359 0.6272
NCI-H1963 CTRP1 7.6474 9.3779 7.4209 21.8893
NCI-H1792 CTRP1 7.7997 14.5186 2.3715 13.179
NCI-H2342 CTRP1 8.3344 10.3925 7.722 15.4098
HCC1833 CTRP1 8.4645 9.9505 8.0556 11.846
NCI-H1105 CTRP1 8.4685 12.5371 6.8062 22.0698
T3M-10 CTRP1 8.4855 12.0869 7.044 20.2224
NCI-H1666 CTRP1 8.5228 16.7461 1.7881 14.6792
NCI-H2122 CTRP1 8.5376 10.9857 7.6328 15.1398
NCI-H3255 CTRP1 8.5545 11.6386 7.3278 17.6288
SCLC-21H CTRP1 8.7059 11.4378 7.5638 14.9271
NCI-H596 CTRP1 8.741 10.8542 7.8843 11.9671
CAL-12T CTRP1 8.7471 9.739 8.4336 7.0747
HCC15 CTRP1 8.8415 12.8269 6.9908 18.9517
NCI-H2141 CTRP1 8.8976 10.5241 8.1879 8.5438
NCI-H441 CTRP1 9.0047 12.0652 7.5104 14.0478
NCI-H1836 CTRP1 9.0173 10.8533 8.1268 8.572
NCI-H1755 CTRP1 9.0417 11.3486 7.8997 10.4999
HCC1359 CTRP1 9.1771 10.7046 8.3324 6.0747
NCI-H841 CTRP1 9.192 11.1538 8.1202 7.921
NCI-H460 CTRP1 9.2604 10.5271 8.4852 4.3939
NCI-H2073 CTRP1 9.3055 14.5546 6.5138 20.3346
NCI-H1781 CTRP1 9.339 11.2695 8.1775 6.8548
NCI-H1694 CTRP1 9.3476 11.0531 8.291 5.813
HCC4006 CTRP1 9.3661 11.0459 8.3083 5.5946
NCI-H2172 CTRP1 9.4226 11.4215 8.1653 6.6645
COLO 699 CTRP1 9.4485 15.6449 6.0847 22.4074
NCI-H2081 CTRP1 9.4732 11.3353 8.2448 5.7881
HCC2935 CTRP1 9.5327 14.6434 6.651 18.5097
HCC1195 CTRP1 9.854 12.1054 8.1365 5.5344
SK-LU-1 CTRP1 9.9074 12.9841 7.7505 8.636
NCI-H1876 CTRP1 9.9602 11.9388 8.2828 4.0245
NCI-H2023 CTRP1 10.0621 11.8719 8.3744 3.0484
HCC2108 CTRP1 10.0632 17.0529 5.8649 21.3607
NCI-H2110 CTRP1 10.2124 19.1291 4.9498 25.2331
Sq-1 CTRP1 10.2939 12.249 8.3375 2.8308
COR-L23 CTRP1 10.3434 12.0237 8.4607 1.8674
HCC827 CTRP1 10.5436 16.5273 6.478 16.101
NCI-H2030 CTRP1 10.547 15.3961 7.0284 12.3159
⏷ Show the Full List of 91 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Oesophagus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KYSE-450 CTRP1 6.6552 8.4085 4.4536 1.4456
KYSE-410 CTRP1 7.2982 12.3196 3.0817 9.837
KYSE-140 CTRP1 7.493 12.2769 3.2201 8.3919
Cancer Drug Sensitivity Data Curated from 26 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JHOS-4 CTRP1 6.5862 9.8422 3.7885 6.3916
COV318 CTRP1 6.9457 8.0687 4.6983 0.1798
SK-OV-3 CTRP1 7.1277 8.617 4.5732 0.447
EFO-21 CTRP1 7.2823 9.1975 4.4214 0.935
OVMANA CTRP1 7.4016 8.9164 4.5696 0.3239
HEY A8 CTRP1 7.9144 13.0018 3.1391 7.991
OVCAR-4 CTRP1 8.05 13.1202 6.1364 28.4672
A2780 CTRP1 8.3551 13.1056 6.4227 25.2087
OVCAR-8 CTRP1 8.5166 15.7391 5.2567 30.4205
OV-90 CTRP1 8.6018 10.5609 7.8997 12.4991
COV434 CTRP1 8.6563 9.7432 8.3424 8.3428
OVKATE CTRP1 8.7478 10.2058 8.2092 9.0509
RMUG-S CTRP1 8.7656 12.7695 6.9539 19.5748
OVK18 CTRP1 8.9829 16.4511 5.2993 28.2507
Caov-3 CTRP1 9.007 10.0607 8.5142 5.1286
TYK-nu CTRP1 9.1693 10.8921 8.2326 7.0019
IGROV-1 CTRP1 9.2746 11.5937 7.9665 8.9725
COV362 CTRP1 9.31 11.5462 8.0178 8.3825
JHOM-1 CTRP1 9.3881 11.8038 7.9502 8.6911
OV7 CTRP1 9.4438 11.668 8.0595 7.5246
RMG-I CTRP1 9.4665 13.9618 6.9383 16.7203
COV644 CTRP1 9.4735 13.0128 7.4159 12.9496
EFO-27 CTRP1 9.7445 12.9959 7.6284 10.2007
JHOC-5 CTRP1 10.197 11.9127 8.4317 2.3342
OAW42 CTRP1 10.2755 11.1822 8.7621 0.3014
SNU-840 CTRP1 11.316 17.8264 6.3835 14.3953
⏷ Show the Full List of 26 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 10 Cell Line(s) in Pancreas Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HPAC CTRP1 6.5509 8.6351 4.3078 2.5525
HuP-T4 CTRP1 6.5836 8.7265 4.2857 2.6468
PaTu 8902 CTRP1 6.7926 8.4641 4.4936 1.0593
SUIT-2 CTRP1 6.8683 8.9613 4.3298 1.8964
QGP-1 CTRP1 6.8876 9.2419 4.2231 2.5483
KP-3 CTRP1 6.998 9.8347 4.0277 3.6898
Panc 03.27 CTRP1 7.1273 9.2616 4.3295 1.5576
CFPAC-1 CTRP1 7.6341 9.7301 4.3661 0.8862
Panc 10.05 CTRP1 7.643 9.5378 4.4399 0.6003
Capan-2 CTRP1 7.8771 13.8986 2.7085 10.8946
⏷ Show the Full List of 10 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Pleura Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H2052 CTRP1 6.8955 10.5186 3.6653 6.5766
MSTO-211H CTRP1 7.2013 9.5733 4.2389 1.9827
NCI-H28 CTRP1 7.265 10.3188 3.9602 3.6674
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Prostate Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
PaCa-3 CTRP1 6.032 7.6472 4.4575 2.4774
Cancer Drug Sensitivity Data Curated from 9 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Hs 936.T CTRP1 6.6278 11.3353 3.1122 11.4596
Hs 944.T CTRP1 6.7511 9.9876 3.8212 5.7365
Hs 852.T CTRP1 6.8779 9.0627 4.2929 2.1123
G-361 CTRP1 6.9049 12.171 2.8986 12.1808
COLO 741 CTRP1 7.429 9.5424 4.3521 1.121
SK-MEL-5 CTRP1 8.9353 11.1387 7.9142 10.8251
SK-MEL-1 CTRP1 9.0995 10.605 8.3194 6.4988
A-375 CTRP1 9.462 10.9663 8.4167 4.3174
SK-MEL-28 CTRP1 9.9683 10.7348 8.8045 0.3546
⏷ Show the Full List of 9 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
G-401 CTRP1 7.8753 13.5568 2.8645 9.8933
HT-1080 CTRP1 9.351 12.1009 7.7739 10.3756
RKN CTRP1 9.4035 11.3092 8.2064 6.3671
Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Stomach Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NUGC-4 CTRP1 7.123 13.8978 2.2189 15.9399
MKN7 CTRP1 7.1311 8.6927 4.5473 0.5354
SH-10-TC CTRP1 7.1732 9.4191 4.2878 1.7355
MKN74 CTRP1 7.1748 10.4774 3.8436 4.6499
Fu97 CTRP1 7.2951 8.8832 4.5417 0.4577
AGS CTRP1 7.6291 9.9306 7.1969 23.7558
SNG-M CTRP1 7.6307 9.2273 4.5448 0.297
⏷ Show the Full List of 7 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Upper Aerodigestive Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HSC-2 CTRP1 6.3758 8.5101 4.2678 3.1793
SCC-9 CTRP1 9.4098 12.9073 7.4187 13.1698
Cancer Drug Sensitivity Data Curated from 5 Cell Line(s) in Urinary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
UM-UC-3 CTRP1 6.634 9.3171 4.055 4.2263
RT-4 CTRP1 6.6434 8.6216 4.3605 2.0406
KMBC-2 CTRP1 7.1038 10.0605 3.9864 3.7804
HT-1376 CTRP1 7.8589 9.7532 4.4447 0.4694
5637 CTRP1 8.1385 9.9669 4.4719 0.29

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Zileuton
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Aminophylline DML2NIB Moderate Decreased metabolism of Zileuton caused by Aminophylline mediated inhibition of CYP450 enzyme. Asthma [CA23] [16]
Roflumilast DMPGHY8 Moderate Decreased metabolism of Zileuton caused by Roflumilast mediated inhibition of CYP450 enzyme. Asthma [CA23] [17]
Coadministration of a Drug Treating the Disease Different from Zileuton (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Arn-509 DMT81LZ Moderate Increased metabolism of Zileuton caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [17]
Bepridil DM0RKS4 Minor Decreased metabolism of Zileuton caused by Bepridil mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [18]
Nifedipine DMSVOZT Minor Decreased metabolism of Zileuton caused by Nifedipine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [18]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Zileuton and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [19]
Obeticholic acid DM3Q1SM Moderate Decreased metabolism of Zileuton caused by Obeticholic acid mediated inhibition of CYP450 enzyme. Autoimmune liver disease [DB96] [20]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Zileuton caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [21]
Telithromycin DMZ4P3A Moderate Decreased metabolism of Zileuton caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [22]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Zileuton and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [23]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Zileuton caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [24]
Tucatinib DMBESUA Moderate Decreased metabolism of Zileuton caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [25]
Alpelisib DMEXMYK Moderate Increased metabolism of Zileuton caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [26]
Levobupivacaine DM783CH Moderate Decreased metabolism of Zileuton caused by Levobupivacaine mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [17]
Oxtriphylline DMLHSE3 Moderate Decreased metabolism of Zileuton caused by Oxtriphylline mediated inhibition of CYP450 enzyme. Cough [MD12] [16]
Mifepristone DMGZQEF Moderate Decreased metabolism of Zileuton caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [27]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Zileuton caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [28]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Zileuton caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [29]
Nefazodone DM4ZS8M Moderate Decreased metabolism of Zileuton caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [30]
PMID28870136-Compound-49 DMTUC9E Moderate Decreased metabolism of Zileuton caused by PMID28870136-Compound-49 mediated inhibition of CYP450 enzyme. Discovery agent [N.A.] [31]
Cenobamate DM8KLU9 Moderate Increased metabolism of Zileuton caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [32]
Stiripentol DMMSDOY Moderate Decreased metabolism of Zileuton caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [17]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Zileuton and Cannabidiol. Epileptic encephalopathy [8A62] [17]
Itraconazole DMCR1MV Moderate Decreased metabolism of Zileuton caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [33]
Carvedilol DMHTEAO Moderate Decreased metabolism of Zileuton caused by Carvedilol. Heart failure [BD10-BD1Z] [18]
Rifapentine DMCHV4I Moderate Increased metabolism of Zileuton caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [34]
Saquinavir DMG814N Moderate Decreased metabolism of Zileuton caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [35]
Etravirine DMGV8QU Moderate Increased metabolism of Zileuton caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [36]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Zileuton and Mipomersen. Hyper-lipoproteinaemia [5C80] [37]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Zileuton and Teriflunomide. Hyper-lipoproteinaemia [5C80] [38]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Zileuton and BMS-201038. Hyper-lipoproteinaemia [5C80] [39]
Acebutolol DM0TI4U Moderate Decreased metabolism of Zileuton caused by Acebutolol. Hypertension [BA00-BA04] [18]
Penbutolol DM4ES8F Moderate Decreased metabolism of Zileuton caused by Penbutolol. Hypertension [BA00-BA04] [18]
Nebivolol DM7F1PA Moderate Decreased metabolism of Zileuton caused by Nebivolol. Hypertension [BA00-BA04] [18]
Levamlodipine DM92S6N Minor Decreased metabolism of Zileuton caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [18]
Pindolol DMD2NV7 Moderate Decreased metabolism of Zileuton caused by Pindolol. Hypertension [BA00-BA04] [18]
Conivaptan DM1V329 Moderate Decreased metabolism of Zileuton caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [40]
Pirfenidone DM6VZFQ Moderate Decreased metabolism of Zileuton caused by Pirfenidone mediated inhibition of CYP450 enzyme. Idiopathic interstitial pneumonitis [CB03] [17]
Givosiran DM5PFIJ Moderate Decreased metabolism of Zileuton caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [41]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Zileuton caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [42]
Ramelteon DM7IW9J Moderate Decreased metabolism of Zileuton caused by Ramelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [43]
Tasimelteon DMLOQ1V Moderate Decreased metabolism of Zileuton caused by Tasimelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [44]
Alosetron DML2A03 Moderate Decreased metabolism of Zileuton caused by Alosetron mediated inhibition of CYP450 enzyme. Irritable bowel syndrome [DD91] [45]
Brigatinib DM7W94S Moderate Increased metabolism of Zileuton caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [46]
PF-06463922 DMKM7EW Moderate Increased metabolism of Zileuton caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [47]
Osimertinib DMRJLAT Moderate Increased metabolism of Zileuton caused by Osimertinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [48]
Capmatinib DMYCXKL Moderate Decreased metabolism of Zileuton caused by Capmatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [49]
Selpercatinib DMZR15V Moderate Decreased metabolism of Zileuton caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [17]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Zileuton and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [50]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Zileuton and Idelalisib. Mature B-cell leukaemia [2A82] [51]
IPI-145 DMWA24P Moderate Decreased metabolism of Zileuton caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [52]
Vemurafenib DM62UG5 Moderate Decreased metabolism of Zileuton caused by Vemurafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [53]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Zileuton caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [17]
Exjade DMHPRWG Moderate Decreased metabolism of Zileuton caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [54]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Zileuton caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [17]
Nilotinib DM7HXWT Moderate Decreased metabolism of Zileuton caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [55]
Olaparib DM8QB1D Moderate Increased metabolism of Zileuton caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [27]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Zileuton caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [56]
Rasagiline DM3WKQ4 Major Decreased metabolism of Zileuton caused by Rasagiline mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [27]
Abametapir DM2RX0I Moderate Decreased metabolism of Zileuton caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [57]
Lefamulin DME6G97 Moderate Decreased metabolism of Zileuton caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [58]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Zileuton caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [59]
Enzalutamide DMGL19D Moderate Increased metabolism of Zileuton caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [60]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Zileuton and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [61]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Zileuton and Leflunomide. Rheumatoid arthritis [FA20] [38]
Asenapine DMSQZE2 Moderate Decreased metabolism of Zileuton caused by Asenapine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [62]
Pimozide DMW83TP Major Decreased metabolism of Zileuton caused by Pimozide mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [27]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Zileuton caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [17]
Larotrectinib DM26CQR Moderate Decreased metabolism of Zileuton caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [27]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Zileuton and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [17]
Armodafinil DMGB035 Minor Increased metabolism of Zileuton caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [63]
LEE011 DMMX75K Moderate Decreased metabolism of Zileuton caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [64]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Zileuton caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [65]
Sirolimus DMGW1ID Moderate Increased plasma concentrations of Zileuton and Sirolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [61]
Tacrolimus DMZ7XNQ Moderate Increased plasma concentrations of Zileuton and Tacrolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [61]
⏷ Show the Full List of 73 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Crospovidone E00626 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Glyceryl dibehenate E00537 22477175 Binding agent; Coating agent; Flavoring agent; Modified-release agent; Viscosity-controlling agent; lubricant
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 13 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Zileuton 600 mg tablet 600 mg 12 HR Extended Release Oral Tablet Oral
Zileuton 600 mg tablet 600 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Zileuton FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5297).
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 5-lipoxygenase inhibitor zileuton attenuates ischemic brain damage: involvement of matrix metalloproteinase 9. Neurol Res. 2009 Oct;31(8):848-52.
7 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
8 Identification of the human liver cytochrome P450 enzymes involved in the metabolism of zileuton (ABT-077) and its N-dehydroxylated metabolite, Abbott-66193. Drug Metab Dispos. 1995 Oct;23(10):1163-74.
9 Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218.
10 Prostaglandins and leukotriene B4 are potent inhibitors of 11beta-hydroxysteroid dehydrogenase type 2 activity in human choriocarcinoma JEG-3 cells. Biol Reprod. 1999 Jul;61(1):40-5.
11 Palmitate increases the susceptibility of cells to drug-induced toxicity: an in vitro method to identify drugs with potential contraindications in patients with metabolic disease. Toxicol Sci. 2012 Oct;129(2):346-62. doi: 10.1093/toxsci/kfs208. Epub 2012 Jun 14.
12 Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos. 2003 Nov;31(11):1352-60.
13 Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5591-4.
14 Zileuton, a new efficient and safe systemic anti-acne drug. Dermatoendocrinol. 2009 May;1(3):188-92. doi: 10.4161/derm.1.3.8368.
15 5-lipoxygenase pharmacogenetics in asthma: overlap with Cys-leukotriene receptor antagonist loci. Pharmacogenet Genomics. 2009 Mar;19(3):244-7. doi: 10.1097/FPC.0b013e328326e0b1.
16 Granneman GR, Braeckman RA, Locke CS, Cavanaugh JH, Dube LM, Awni WM "Effect of zileuton on theophylline pharmacokinetics." Clin Pharmacokinet 29(suppl 2 (1995): 77-83. [PMID: 8620674]
17 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
18 Product Information. Zylo Filmtab (zileuton). Abbott Pharmaceutical, Abbott Park, IL.
19 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
20 Product Information. Ocaliva (obeticholic acid). Intercept Pharmaceuticals, Inc., New York, NY.
21 Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
22 Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
23 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
24 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
25 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
26 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
27 Cerner Multum, Inc. "Australian Product Information.".
28 Product Information. Isturisa (osilodrostat). Recordati Rare Diseases Inc, Lebanon, NJ.
29 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
30 Product Information. Serzone (nefazodone). Bristol-Myers Squibb, Princeton, NJ.
31 Magnusson M, Bergstrand IC, Bjorkman S, Heijl A, Roth B, Hoglund P "A placebo-controlled study of retinal blood flow changes by pentoxifylline and metabolites in humans." Br J Clin Pharmacol 61 (2006): 138-47. [PMID: 16433868]
32 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
33 Auclair B, Berning SE, Huitt GA, Peloquin CP "Potential interaction between itraconazole and clarithromycin." Pharmacotherapy 19 (1999): 1439-44. [PMID: 10600094]
34 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
35 Product Information. Fortovase (saquinavir) Roche Laboratories, Nutley, NJ.
36 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
37 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
38 Canadian Pharmacists Association.
39 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
40 Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
41 Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
42 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
43 Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
44 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
45 Product Information. Lotronex (alosetron). Glaxo Wellcome, Research Triangle Park, NC.
46 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
47 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
48 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
49 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
50 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
51 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
52 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
53 Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
54 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
55 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
56 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
57 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
58 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
59 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
60 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
61 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
62 Product Information. Saphris (asenapine). Schering-Plough Corporation, Kenilworth, NJ.
63 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
64 DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
65 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.